

## Weekly COVID-19 Breakthrough Infections Report

**Clark County, Nevada** 

## Date: February 24, 2022

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations








Table 1: Population Characteristics of COVID-19 Breakthrough Cases

	Overa	
	N	%
All	67611	100
Age (in years)		
5-17	4593	
18-24	6646	-
25-49	31251	
50-64	15004	
65+	10117	15
Gender		
Male	28749	43
Female	38371	57
Unknown	491	1
Race/Ethnicity		
Hispanic	13960	21
White	20318	30
Black	4939	7
API	8453	13
AEA	48	0
Other	5931	9
Unknown	13962	21
Travel History		
Yes	2041	3
No	13786	20
Unknown	51784	77
Hospitalization		
Yes	1162	2
No	15376	23
Unknown	51073	76
Death		
Yes	445	1
No	3519	5
Unknown	63647	94
Vaccine Type		
Pfizer	47971	71
Unknown	528	1
Moderna	18797	28
Janssen	315	0
<b>Underlying Conditions</b>		
Yes	6809	10
No	60802	90

**Table 2: Breakthrough Case Rates** 

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
1276418	67611	1041756	419516	5297	40270

<sup>\*</sup> Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson salphasen vaccine.



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations

	Over	Overall	
	Ν	%	
All	1162	100	
Age (in years)			
5-17	4	0	
18-24	10	1	
25-49	109	9	
50-64	200	17	
65+	839	72	
Gender			
Male	645	56	
Female	515	44	
Unknown	2	0	
Race/Ethnicity			
Hispanic	158	14	
White	662	57	
Black	128	11	
API	109	9	
AEA	3	0	
Other	33	3	
Unknown	69	6	
Travel History			
Yes	50	4	
No	627		
Unknown	485	42	
Death			
Yes	346	30	
No	159	14	
Unknown	657	57	
Vaccine Type			
Pfizer	739	64	
Unknown	33	3	
Moderna	386	33	
Janssen	4	0	
Underlying Conditions			
Yes	755	65	
No	407	35	



Table 4:Population Characteristics of COVID-19 Breakthrough Deaths

	Ove	Overall	
	Ν	%	
All	445	100	
Age (in years)			
25-49	12	3	
50-64	58	13	
65+	375	84	
Gender			
Male	279	63	
Female	165	37	
Unknown	1	0	
Race/Ethnicity			
Hispanic	58	13	
White	275	62	
Black	47	11	
API	46	10	
AEA	2	0	
Other	6	1	
Unknown	11	2	
Variant of concern (VOC)			
Epsilon	1	0	
Delta	16	4	
Alpha	1	0	
Unknown	427	96	
Hospitalization			
Yes	346	78	
No	19	4	
Unknown	80	18	
Vaccine Type			
Pfizer	282	63	
Unknown	14	3	
Moderna	147	33	
Janssen	2	0	
Underlying Conditions			
Yes	208	47	
No	237	53	

**Table 5: Breakthrough Death Rates** 

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
1276418	445	1041756	6961	35	668

<sup>\*</sup> Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson salanssen vaccine.



Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	755	65
	No	407	35
Hypertension	Yes	469	N/A
Immunocompromised	Yes	47	N/A
Chronic Heart Disease	Yes	247	N/A
Chronic Liver Disease	Yes	25	N/A
Chronic Kidney Disease	Yes	146	N/A
Diabetes	Yes	298	N/A
Neurologic/Neurodevelopmental	Yes	76	N/A
Chronic Lung Disease	Yes	212	N/A
Historically Healthy	Yes	109	N/A

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	208	47
	No	237	53
Hypertension	Yes	139	N/A
Immunocompromised	Yes	17	N/A
Chronic Heart Disease	Yes	79	N/A
Chronic Liver Disease	Yes	5	N/A
Chronic Kidney Disease	Yes	49	N/A
Diabetes	Yes	88	N/A
Neurologic/Neurodevelopmental	Yes	20	N/A
Chronic Lung Disease	Yes	64	N/A
Historically Healthy	Yes	7	N/A

## Notes:

<sup>\*</sup> White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

<sup>\*</sup> The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

<sup>\*</sup> The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).